KMT2D and IGF2 Genes Expression in Breast Cancer Patients

Alireza Tavakolpour Negari, Alireza Emamvirdizadeh, Mahta Majdnia, Arash Matin Ahmadi, Fatemeh Shahbazi, Ameneh Molaei, Seyed Hesamoddin Bidooki

Abstract


Background: Breast cancer which is often a cancer in women, is one of the most important public health problems and 1,384,155 new cases worldwide are associated with 459,000 deaths. Breast cancer is highly heterogeneous in its pathological characteristics. Current predictions and statistics suggest that both worldwide incidence of breast cancer and related mortality are on the rise. So far, many studies have been conducted on various genes in breast cancer that can help to treat this cancer. Methods: The gene expression of KMT2D and IGF2 were investigated in 35 samples with breast cancer after genomic RNA extraction and synthesis cDNA using quantitative real-time PCR method. Result: There was no significant difference in the expression of KMT2D and IGF2 genes in breast tumor samples compared to adjacent normal samples (P > 0.05). However, this study was designed as a pilot study, and further investigations are required to confirm our findings.


Keywords


Gene Expression; KMT2D; IGF2; Quantitative Real-Time PCR Method; Breast Cancer.

Full Text:

PDF

References


AHMADI AM, GHASEMI H, NOOSHIN S, ZAYANI Z, KARIZI SZ AND KARIMIPOOR M. 2018. Assessing Gene Expression and Methylation of KMT2D and IGF2 Genes in Patients with Non-Small Cell Lung Cancer. Cancer and Clinical Oncology 7: 55.

ANDERSON WF, CHATTERJEE N, ERSHLER WB AND BRAWLEY OW. 2002. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast cancer research and treatment 76: 27-36.

AUGERT A, ZHANG Q, BATES B, CUI M, WANG X, WILDEY G, DOWLATI A AND MACPHERSON D. 2017. Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). Journal of Thoracic Oncology 12: 704-713.

BANEGAS MP, BIRD Y, MORAROS J, KING S, PRAPSIRI S AND THOMPSON B. 2012. Breast cancer knowledge, attitudes, and early detection practices in United States-Mexico border Latinas. Journal of Women's Health 21: 101-107.

BARROW TM AND MICHELS KB. 2014. Epigenetic epidemiology of cancer. Biochemical and biophysical research communications 455: 70-83.

COLDITZ GA AND ROSNER B. 2000. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. American journal of epidemiology 152: 950-964.

DALGLIESH GL, FURGE K, GREENMAN C, CHEN L, BIGNELL G, BUTLER A, DAVIES H, EDKINS S, HARDY C AND LATIMER C. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463: 360.

DAWKINS JB, WANG J, MANIATI E, HEWARD JA, KONIALI L, MARTIN SA, CHELALA C, BALKWILL FR, FITZGIBBON J AND GROSE RP. 2016. Reduced expression of histone methyltransferases KMT2C and KMT2D correlates with improved outcome in pancreatic ductal adenocarcinoma. Cancer research: canres. 0481.2016.

ELLIS MJ, JENKINS S, HANFELT J, REDINGTON ME, TAYLOR M, LEEK R, SIDDLE K AND HARRIS A. 1998. Insulin-like growth factors in human breast cancer. Breast cancer research and treatment 52: 175-184.

FERNANDEZ AM AND TORRES-ALEMÁN I. 2012. The many faces of insulin-like peptide signalling in the brain. Nature Reviews Neuroscience 13: 225.

GUI Y, GUO G, HUANG Y, HU X, TANG A, GAO S, WU R, CHEN C, LI X AND ZHOU L. 2011. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature genetics 43: 875.

GUO C, CHEN LH, HUANG Y, CHANG C-C, WANG P, PIROZZI CJ, QIN X, BAO X, GREER PK AND MCLENDON RE. 2013. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 4: 2144.

JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, MURRAY T AND THUN MJ. 2008. Cancer statistics, 2008. CA: a cancer journal for clinicians 58: 71-96.

KIM J-H, SHARMA A, DHAR SS, LEE S-H, GU B, CHAN C-H, LIN H-K AND LEE MG. 2014. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer research 74: 1705-1717.

LIU L, KIMBALL S, LIU H, HOLOWATYJ A AND YANG Z-Q. 2015. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget 6: 2466.

LV S, JI L, CHEN B, LIU S, LEI C, LIU X, QI X, WANG Y, LEUNG EL-H AND WANG H. 2017. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene: 1.

NAFISSI N, SAGHAFINIA M, MOTAMEDI MHK AND AKBARI ME. 2012. A survey of breast cancer knowledge and attitude in Iranian women. Journal of cancer research and therapeutics 8: 46.

PORTER P. 2008. “Westernizing” women's risks? Breast cancer in lower-income countries. New England Journal of Medicine 358: 213-216.

SHETTY PJ, MOVVA S, PASUPULETI N, VEDICHERLLA B, VATTAM KK, VENKATASUBRAMANIAN S, AHUJA YR AND HASAN Q. 2011. Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. Journal of cancer research and clinical oncology 137: 339-345.

TAO Z, SHI A, LU C, SONG T, ZHANG Z AND ZHAO J. 2015. Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics 72: 333-338.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Alireza Tavakolpour Negari

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.